Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult Grade III Meningioma Clear all
Completed Phase 2 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
Interventions
Armodafinil, placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
hydroxyurea, imatinib mesylate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced May 21, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced May 21, 2026, 4:47 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent Meningioma
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Drug · Procedure
Lead sponsor
Nancy Ann Oberheim Bush, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
temsirolimus, pharmacological study, cytokine levels
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced May 21, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
imatinib mesylate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma, Adult Meningioma, Recurrent Adult Brain Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced May 21, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
54 Gy radiotherapy, 60 Gy radiotherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced May 21, 2026, 4:47 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Interventions
exercise intervention, educational intervention, physiologic testing, management of therapy complications, mind-body intervention procedure, Measurement of stress-related hormones
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced May 21, 2026, 4:47 PM EDT